Opioid receptor three-dimensional structures from distance geometry calculations with hydrogen bonding constraints

Biophysical Journal

Volumn 75, Issue 2, 1998, Pages 612-634

  Pogozheva, Irina D ^a   Lomize, Andrei L ^a   Mosberg, Henry I ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE RECEPTOR; RECEPTOR SUBTYPE;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CROSS LINKING; HYDROGEN BOND; LIGAND BINDING; MOLECULAR INTERACTION; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; STRUCTURE ANALYSIS;

EID: 0031848224     PISSN: 00063495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3495(98)77552-6     Document Type: Article

References (141)

1. Alkorta, I., and G. Loew. 1996. A 3D model of the δ opioid receptor and ligand-receptor complexes. Protein Eng. 9:573-583.
2. Baldwin, E. P., O. Hajiseyedjavadi, W. A. Baase, and B. W. Matthews. 1993. The role of backbone flexibility in the accomodation of variants that repack the core of T4 lysozyme. Science. 262:1715-1718.
3. Baldwin, E., J. Xu, O. Hajiseyedjavadi, W. A. Baase, and B. W. Matthews. 1996. Thermodynamic and structural compensation in "size-switch" core repacking variants of bacteriophage T4 lysozyme. J. Mol. Biol. 121:542-559.
4. Baldwin, J. M. 1993. The probable arrangement of the helices in G protein-coupled receptors. EMBO J. 12:1693-1703.
5. Baldwin, J. M. 1997. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptos. J. Mol. Biol. 272:144-164.
6. Ballesteros, J. A., and H. Weinstein. 1995. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25:366-427.
7. Barlow, D. J., and J. M. Thornton. 1988. Helix geometry in proteins. J. Mol. Biol. 201:601-619.
8. Befort, K., L. P. Tabbara, S. Bausch, C. Chavkin, C. Evans, and B. L Kieffer. 1996a. The conserved aspartate residue in the third putative transmembrane domain of the δ-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. Mol. Pharmacol. 49:216-223.
9. Befort, K., L. P. Tabbara, D. Kling, B. Maigret, and B. L. Kieffer. 1996b. Role of aromatic transmembrane residues of the δ-opioid receptor in ligand recognition. J. Biol. Chem. 271:10161-10168.
10. Bernstein, F. C., T. F. Koetzle, G. J. Williams, E. E. Meyer, M. D. Brice, J. R. Rodgers, O. Kennard, T. Shimanouchi, and M. Tasumi. 1977. The Protein Data Bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 112:535-542.
11. Bidlack, J. M., D. K. Frey, A. Seyed-Mozaffari, and S. Archer. 1989. 14-β-(Bromoacetamido)morphine irreversible labels μ-opioid receptor in rat brain membranes. Biochemistry. 28:4333-4339.
12. Brooks, B. R., E. R. Bruccoleri, E. R. Olafson, D. J. States, S. Swaminathan, and M. Karplus. 1983. CHARMM: a program for macromolecular energy, minimization and dynamics calculations. J. Comput. Chem. 4:187-217.
13. Bye, E. 1976. The crystal structure of morphine hydrate. Acta Chem. Scand. 630:549-554.
14. Calderon, S. N., K. C. Rice, R. B. Rothman, F. Porreca, J. L. Flippen-Anderson, H. Kayakiri, H. Xu, K. Beckets, L. E. Smith, E. J. Bilsky, P. Davis, and R. Horvath. 1997. Probes for narcotic receptor mediated phenomena. 23. Synthesis, opioid receptor binding, and bioassay of the highly selective 5 agonist (+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3- methoxybenzyl]-N,N-diethylbenzamide (SNC 80) and related novel nonpeptide δ opioid receptor ligands. J. Med. Chem. 40:695-704.
15. Cappelli, A., M. Anzini, S. Vomero, C. M. Menziani, P. G. De-Benedetti, M. Sbacchi, G. D. Clarke, and L. Mennuni. 1996. Synthesis, biological evaluation, and quantitive receptor docking simulation of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for κ-opioid receptors. J. Med. Chem. 39: 860-872.
16. Casy, A. F., and R. T. Parfitt. 1986. Opioid Analgesics: Chemistry and Receptors. Plenum Press, New York.
17. Chakrabarti, S., W. Yang, P. Y. Law, and H. H. Loh. 1997. The mu-opioid receptor down-regulates differently from the delta-opioid receptor: requirement of a high affinity receptor/G protein complex formation. Mol. Pharmacol. 52:105-113.
18. Chang, A.-C., A. E. Takemori, W. H. Ojala, W. B. Gleanson, and P. S. Portoghese. 1994. κ-Opioid receptor selective affinity labels, electrophilic benzeneacetamides as κ-selective opioid antagonists. J. Med. Chem. 3:4490-4498.
19. Chen, C., J.-C. Xue, J. Zhu, Y.-W. Chen, S. P. Kunapuli, J. K. de Riel, L. Yu, and L.-Y. Liu-Chen. 1995. Characterization of irreversible binding of β-funaltrexamine to the cloned rat μ-opioid receptor. J. Biol. Chem. 270:17866-17870.
20. 3H]β-funaltrexamine covalent binding in the cloned rat μ-opioid receptor. J. Biol. Chem. 271:21422-21429.
21. Chothia, C., and A. M. Lesk. 1985a. Helix movements and the reconstruction of the haem pocket during the evolution of the cytochrome c family. J. Mol. Biol. 182:151-158.
22. Chothia, C., and A. M. Lesk. 1985b. Helix movements in proteins. Trends Biochem. Sci. 10:116-119.
23. Claude, P. A., D. R. Wotta, X. H. Zhang, P. L. Prather, T. M. McGinn, L. J. Erickson, H. H. Lon, and P. Y. Law. 1996. Mutation of a conserved serine in TM4 of opioid receptors confers full agonistic properties to classical antagonists. Proc. Natl. Acad. Sci. USA. 93:5715-5719.
24. 3]DPDPE. J. Am. Chem. Soc. 118:2143-2152.
25. Daopin, S., T. Alber, W. A. Baase, J. A. Wozniak, and B. W. Matthews. 1991. Structural and thermodynamic analysis of the packing of two α-helices in bacteriophage T4 lysozyme. J. Mol. Biol. 221:647-667.
26. Davies, A., G. F. X. Schertler, B. E. Gowen, and H. R. Saibil. 1996. Projection structure of an invertebrate rhodopsin. J. Struct. Biol. 117: 36-44.
27. deAlba, E., M. A. Jiménez, M. Rico, and J. Nieto. 1996. Conformational investigation of designed short linear peptides able to fold into β-hairpin structures in aqueous solution. Folding Design. 1:133-144.
28. Deisenhofer, J., and H. Michel. 1991. Structures of bacterial photosynthetic reaction centers. Annu. Rev. Cell Biol. 7:1-23.
29. Deschamps, J. R., C. George, and J. L. Flippen-Anderson. 1996. Structural studies of opioid peptides: a review of recent progress in x-ray diffraction studies. Biopolymers. 40:121-139.
30. Dhawan, B. N., F. Cesselin, R. Raghubir, T. Reisine, P. B. Bradley, P. S. Portoghese, and M. Hamon. 1996. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol. Rev. 48:567-592.
31. Doi, M., T. Ishida, and M. Inoue. 1990. Conformational characteristics of opioid κ-receptor agonist: crystal structure of (5S,7S,8S)-(-)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl] benzeneacetamide (U69, 593), and conformational comparison with some κ-agonists. Chem. Pharm. Bull. 38:1815-1818.
32. Donnelly, D., J. B. C. Findlay, and T. L. Blundell. 1994. The evolution and structure of aminergic G protein-coupled receptors. Receptors Channels. 2:61-78.
33. Elling, C. E., S. M. Nielsen, and T. W. Schwartz. 1995. Conversion of antagonist-binding site to metal-ion site in the tachikinin NK-1 receptor. Nature. 374:74-77.
34. Eriksson, A. E., W. A. Baase, X.-J. Zhang, D. W. Heinz, M. Blaber, E. P. Baldwin, and B. W. Matthews. 1992. Response of a protein structure to cavity-creating mutations and its relation to the hydrophobic effects. Science. 255:178-183.
35. Fahmy, K., F. Siebert, and T. P. Sakmar. 1995. Photoactivated state of rhodopsin and how it can form. Biophys. Chem. 56:171-181.
36. Farrens, D. L., C. Altenbach, K. Yang, W. L. Hubbell, and H. G. Khorana. 1996. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science. 274:768-770.
37. 583 in the third extracellular loop of the lutropin/choriogonadotropin receptor is critical for signaling. J. Biol. Chem. 271:925-930.
38. Flippen-Anderson, J. L., and C. George. 1994. X-ray structure of potent opioid receptor ligands: etonitazene, cis-(+)-3-methylfentanyl, etorphine, diprenorphine, and buprenorphine. Heterocycles. 39:751-766.
39. 5]enkephalin, a highly potent, δ opioid receptor-selective compound: comparisons with proposed solution conformations. J. Am. Chem. Soc. 116:7523-7531.
40. Fraser, C. M., C.-D. Wang, D. A. Robinson, J. D. Gocayne, and J. C. Venter. 1989. Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol. Pharmacol. 36:840-847.
41. Froimowitz, M. 1990. Conformational search in enkephalin analogues containing a disulfide bond. Biopolymers. 30:1011-1025.
42. Fu, D., J. A. Ballesteros, H. Weinstein, J. Chen, and J. A. Javitch. 1996. Residues I the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. Biochemistry. 35: 11278-11285.
43. Fukuda, K., K. Terasako, S. Kato, and K. Mori. 1995. Identification of the amino acid residues involved in selective agonist binding in the first extracellular loop of the δ- and μ-opioid receptors. FEBS Lett. 373: 177-181.
44. Griffin, J. F., D. L. Larson, and P. S. Portoghese. 1986. Crystal structure of α- and β-funaltrexamine: conformational requirements of the fumaramate moiety in the irreversible blockage of μ opioid receptors. J. Med. Chem. 29:778-783.
45. Grigorieff, N., T. A. Ceska, K. H. Downing, J. M. Baldwin, and R. Henderson. 1996. Electron-crystallographic refinement of the structure of bacteriorhodopsin. J. Mol. Biol. 259:393-421.
46. Güntert, P., W. Brawn, and K. Wüthrich. 1991. Efficient computation of three-dimensional protein structure in solution from NMR data using the program DIANA and the supporting programs CALIBA, HABAS and GLOMSA. J. Mol. Biol. 217:517-530.
47. Güntert, P., and K. Wüthrich. 1991. Improved efficiency of protein structure calculations from NMR data using the program DIANA with redundant dihedral angle constraints. J. Biomol. NMR. 1:447-456.
48. 3]DPDPE: a new enkephalin analog with unique receptor activity profile. Further evidence of δ-opioid receptor multiplicity. J. Med. Chem. 37:1572-1577.
49. Habibi-Nezhad, B., M. Hanifian, and M. Mahmoudian. 1996. Computer-aided receptor modeling of human opioid receptors (mu, kappa and delta). J. Mol. Model. 2:362-369.
50. Han, M., S. W. Lin, M. Minkova, S. O. Smith, and T. P. Sakmar. 1996a. Functional interaction if transmembrane helices 3 and 6 in rhodopsin. Replacement of phenylalanine 261 by alanine causes reversion of phenotype of a glycine 121 replacement mutant. J. Biol. Chem. 271: 32337-32342.
51. Han, M., S. W. Lin, S. O. Smith, and T. P. Sakmar. 1996b. The effects of amono acid replacements of glycine 121 on transmembrane helix 3 of rhodopsin. J. Biol. Chem. 271:32330-32336.
52. Henderson, R., J. M. Baldwin, T. A. Ceska, F. Zemlin, E. Beckmann, and K. H. Downing. 1990. Model for the structure of bacteriorhodopsin based on high-resolution electron cryo-microscopy. J. Mol. Biol. 213:899-929.
53. Herzyk, P., and R. E. Hubbard. 1995. Automated method for modeling seven-helix transmembrane receptors from experimental data. Biophys. J. 69:2419-2442.
54. Heyl, D. L. 1991. Structural requirements for substitutions in delta opioid receptor selective, cyclic tetrapeptide dermorphin analogs: divergence from related pentapeptide enkephalin analogs. Ph.D. thesis. University of Michigan, Ann Arbor, MI.
55. 3 aromatic moiety in a series of delta receptor-selective dermorphin/ deltorphin-related tetrapeptides: effects on opioid receptor binding. Int. J. Pept. Protein Res. 39:450-457.
56. 3 aromatic ring in cyclic delta receptor-selective dermorphin/deltorphin tetrapeptide analogs: electronic and lipophilic requirements for receptor affinity. J. Med. Chem. 35:1535-1541.
57. Hjorth, S. A., K. Thirstrup, D. K. Grandy, and T. W. Schwartz. 1995. Analysis of selective binding epitope for the κ-opioid receptor antagonist norbinaltorphimine. Mol. Pharmacol. 47:1089-1094.
58. 1A receptor: a site directed mutation study. FEBS Lett. 312:259-262.
59. Ho, J. 1997. Development of a model for the μ opioid receptor pharmacophore. Ph.D. thesis. University of Michigan, Ann Arbor, MI.
60. Housset, D., K.-S Kim,. J. Fuchs, C. Woodward, and A. Wlodawer. 1991. Crystal structure of a Y35G mutant of bovine pancreatic trypsin inhibitor. J. Mol. Biol. 220:757-770.
61. Hwa, S., R. Gaivin, J. E. Porter, and D. M. Perez. 1997. Synergism of constitutive activity in alpha-1-adrenergic receptor. Biochemistry. 36: 633-639.
62. Javitch, J. A., D. Fu, J. Chen, and A. Karlin. 1995. Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method. Neuron. 14:825-831.
63. 2 dopamine receptor is exposed in the binding-site crevice. Proc. Natl. Acad. Sci. USA. 91:10355-10359.
64. Klein, C. L., R. J. Majeste, and E. D. Stevens. 1987. Experimental electron density distribution of naloxone hydrochloride dihydrate, a potent opiate antagonist. J. Am. Chem. Soc. 109:6675-6681.
65. Knapp, R. J., E. Malatynska, N. Collins, L. Fang, J. Y. Wang, V. J. Hruby, W. R. Roeske, and H. I. Yamamura. 1995. Molecular biology and pharmacology of cloned opioid receptors. FASEB J. 9:516-525.
66. Kollman, P. A. 1993. Free energy calculations: applications to chemical and biochemical phenomena. Chem. Rev. 93:2395-2417.
67. Kong, H., K. Raynor, H. Yano, J. Takeda, G. I. Bell, and T. Reisine. 1994. Agonists and antagonists bind to different domains of the cloned κ-opioid receptor. Proc. Natl. Acad. Sci. USA. 91:8042-8046.
68. Kong, H., K. Raynor, H. Yano, K. Yasuda, S. T. Moe, P. S. Portoghese, G. I. Bell, and T. Reisine. 1993. A single residue, aspartic acid 95, in the δ-opioid receptor specifies selective high affinity agonist binding. J. Biol. Chem. 268:23055-23058.
69. 3H]-U69,593, a highly selective ligand for the opioid κ-receptor. Eur. J. Pharmacol. 109:281-284.
70. Lesk, A. M., and C. Chothia. 1980. How different amino acid sequences determine similar protein structures: the structure and evolutionary dynamics of globins. J. Mol. Biol. 136:225-270.
71. 1H NMR data. J. Am. Chem. Soc. 116:429-436.
72. Lomize, A. L., I. D. Pogozheva, and H. I. Mosberg. 1996. Development of a model for the opioid receptor pharmacophore. 3. Comparison of the cyclic tetrapeptide, Tyr-c[D-Cys-Phe-D-Phe]OH with other conformation-ally constrained δ-receptor selective ligands. Biopolymers. 38:221-234.
73. Lomize, A. L., I. D. Pogozheva, and H. I. Mosberg. 1998. Structural organization of G-protein-coupled receptors. Perspect. Drug Discovery Design. (in press).
74. Louie, G. V., and G. D. Brayer. 1989. A polypeptide chain-refolding event occurs in the Gly82 variant of yeast iso-1-cytochrome c. J. Mol. Biol. 209:313-322.
75. Mansour, A., F. Meng, J. H. Meador-Woodruff, L. P. Taylor, O. Civelli, and H. Akil. 1992. Site-directed mutagenesis of the human dopamine D2 receptor. Eur. J. Pharmacol. 227:205-214.
76. Mansour, A., L. P. Taylor, J. L. Fine, R. C. Thompson, M. T. Hoversten, H. I. Mosberg, S. J. Watson, and H. Akil. 1997. Key residues defining the μ opioid receptor binding pocket: a site-directed mutagenesis study. J. Neurochem. 68:344-353.
77. McDonald, I. K., and J. M. Thornton. 1994. Satisfying hydrogen bonding potential in proteins. J. Mol. Biol. 238:777-793.
78. Meng, F., M. T. Hoversten, R. C. Thompson, L. Taylor, S. J. Watson, and H. Akil. 1995. A chimeric study of the molecular basis of affinity and selectivity of the κ and the δ-opioid receptors. J. Biol. Chem. 270: 12730-12736.
79. Meng, F., Y. Ueda, M. T. Hoversten, R. C. Thompson, L. Taylor, S. J. Watson, and H. Akil. 1996. Mapping the receptor domains critical for the binding selectivity of δ-opioid receptor ligands. Eur. J. Pharmacol. 311:285-292.
80. Metzger, T. G., and D. M. Ferguson. 1995. On the role of extracellular loops of opioid receptors in conferring ligand selectivity. FEBS Lett. 375:1-4.
81. Metzger, T. G., M. G. Paterline, P. S. Portoghese, and D. M. Ferguson. 1996. Application of the message-address concept to the docking of naltrexone and selective naltrexone-derived opioid antagonists into opioid receptor models. Neurochem. Res. 21:1287-1294.
82. Minami, M., T. Nakagawa, T. Seki, T. Onogi, Y. Aoki, Y. Katao, S. Katsumata, and M. Satoh. 1996. A single residue, Lys108 of the δ-opioid receptor prevents the μ-opioid selective ligand [D-Ala2,N-MePhe4,Glyol5]enkephalin from binding to the δ-opioid receptor. Mol. Pharmacol. 50:1413-1422.
83. Momany, F. A., and R. Rone. 1992. Validation of the general purpose QUANTA3.2/CHARMm force field. J. Comput. Chem. 13:888-900.
84. Mosberg, H. I., R. K. Dua, I. D. Pogozheva, and A. L. Lomize. 1996. Development of a model for the δ opioid receptor pharmacophore. 4. Residue 3 dehydrophenylalanine analogues of Tyr-cyclo-[D-Cys-Phe-D-Pen]OH (JOM-13) confirm required gauche orientation of aromatic side chain. Biopolymers. 39:287-296.
85. Mosberg, H. I., R. Hurst, V. J. Hruby, K. Gee, H. I. Yamamura, J. J. Galligan, and T. F. Burks. 1983. Bis-penicillinamine enkephalins possess highly improved apecificity toward δ-opioid receptors. Proc. Natl. Acad. Sci. USA. 80:5871-5874.
86. 1 replacements in the cyclic δ-receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13). J. Med. Chem. 37: 4371-4383.
87. 3 replacements in the cyclic δ-receptor selective tetrapeptide Tyr-c[D-Cys-Phe-D-Pen]OH (JOM-13). J. Med. Chem. 37:4384-4391.
88. Mosberg, H. I., J. R. Omnaas, C. B. Smith, and F. Medzihradsky. 1988. Cyclic disulfide- and dithioether-containing opioid tetrapeptides: development of a ligand with enhanced delta opioid receptor selectivity and potency Life Sci. 43:1013-1020.
89. 1H NMR study of HTyr-D-Cys-Phe-D-PenOH (JOM-13), a highly selective ligand for the delta opioid receptor. In Proteins. V. Renugopalakrishnan, editor. ESCOM, Leiden, the Netherlands. 105-109.
90. 5]enkephalin. J. Am. Chem. Soc 112:822-829.
91. Oliveira, L., A. C. M. Paiva, and G. Vriend. 1993. A common motif in G-protein-coupled seven transmembrane helix receptors. J. Computer-Aided Mol. Design. 7:649-658.
92. Onogi, T., M. Minami, Y. Katao, T. Nakagawa, Y. Aoki, T. Toya, S. Katsumata, and M. Satoh. 1995. DAMGO, a μ-opioid receptor selective agonist, distinguishes between μ- and δ-opioid receptors around their first extracellular loops. FEBS Lett. 357:93-97.
93. Pepin, M.-C., S. Y. Yue, E. Roberts, C. Wahlestedt, and P. Walker. 1997. Novel "restoration of function" mutagenesis strategy to identify amino acids of the δ-opioid receptor involved in ligand binding. J. Biol. Chem. 272:9260-9267.
94. Pogozheva, I. D., A. L. Lomize, and H. I. Mosberg. 1997. The transmembrane 7-α-bundle of rhodopsin: distance geometry calculation with hydrogen bonding constraints. Biophys. J. 70:1963-1985.
95. Porter, J. E., J. Hwa, and D. M. Perez. 1996. Activation of the alpha-1b-adrenergic receptor is initiated by disruption of an interhelical salt bridge constraint. J. Biol. Chem. 45:28318-28323.
96. Portoghese, P. S., C.-E. Lin, F. Farour-Grant, and A. E. Takemori. 1994. Structure-activity relationship of N17′-substituted norbinaltorphimine congeners. Role of the N17′ basic group in the interaction with a putative address subsite on the κ opioid receptor. J. Med. Chem. 37: 1495-1500.
97. Portoghese, P. S., A. W. Lipkowski, and A. E. Takemori. 1987. Bimorphinans as highly selective, potent kappa receptor antagonists. J. Med. Chem. 30:238-239.
98. Portoghese, P. S., M. Sultana, and A. E. Takemori. 1990. Design of peptidomimetic δ-opioid receptor antagonists using the message-address concept. J. Med. Chem. 33:1714-1720.
99. Reisine, T. 1995. Opiate receptors. Neuropharmacology. 34:463-472.
100. Richardson, J. S., and D. C. Richardson. 1989. Principles and patterns of protein conformation. In Prediction of Protein Structure and the Principles of Protein Conformation. G. D. Fasman, editor. Plenum Press, New York and London. 2-97.
101. Rohinson, P. R., G. B. Cohen, E. A. Zhukovsky, and D. D. Oprian. 1992. Constitutively active mutants of rhodopsin. Neuron. 9:719-725.
102. Römer, D., H. Buscher, R. C. Hill, R. Maurer, T. J. Petcher, H. B. Welle, H. C. Bakel, A. M. Akkerman. 1980. Bremazocine: a potent, long-acting opiate kappa-agonist. Life Sci. 27:971-978.
103. Sakmar, T. P., and K. Fahmy. 1995. Properties and photoactivity of rhodopsin mutants. Isr. J. Chem. 35:325-337.
104. Savarese, T. M., and C. M. Fraser. 1992. In vitro mutagenesis and the search for structure-function relationships among G-protein-coupled receptors. Biochem. J. 283:1-19.
105. Sauer, U. H., S. Dao-pin, and B. W. Matthews. 1992. Tolerance of T4 lysozyme to proline substitutions within the long interdomain α-helix illustrates the adaptability of protein to potentially destabilizing lesions. J. Biol. Chem. 267:2393-2399.
106. Schertler, G. F. X., C. Villa, and R. Henderson. 1993. Projection structure of rhodopsin. Nature. 362:770-772.
107. Schultz, G. E. 1992. Structure-function relationships in the membrane channel porin as based on 1.8 Å resolution crystal structure. In Membrane Proteins: Structure, Interactions and Models. A. Pullman, J. Jortner, and B. Pullman, editors. KJuwer Academic Publishers, Dordrecht, the Netherlands. 403-412.
108. 2A receptor. J. Biol. Chem. 270:16683-16688.
109. 223 is critical for μ-opioid binding and inactivation by N-ethylmaleimide. J. Biol. Chem. 271:5505-5512.
110. Sheikh, S., T. A. Zviaga, O. Lichtarge, T. P. Sakmar, and H. R. Bourne. 1996. Rhodopsin activation blocked by metal-ion-binding sites linking transmembrane helices c and F. Nature. 383:347-350.
111. Shieh, T., M. Han, T. P. Sakmar, and S. O. Smith. 1997. The steric trigger in rhodopsin activation. J. Mol. Biol. 269:373-384.
112. Sibanda, B. L., and J. M. Thornton. 1991. Conformation of β-hairpins in protein structures: classification and diversity in homologous structures. Methods Enzymol. 202:59-83.
113. Strader, C. D., M. R. Candelore, W. S. Hill, I. S. Sigal, and R. A. F. Dixon. 1989. Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J. Biol. Chem. 264:13572-13578.
114. Strader, C. D., I. S. Sigal, M. R. Candelore, E. Rands, W. S. Hill, and R. A. F. Dixon. 1988. Conserved aspartic acid residues 79 and 113 of the β-adrenergic receptor have different roles in receptor function. J. Biol. Chem. 263:10267-10271.
115. Strader, C. D., I. S. Sigal, R. B. Register, M. R. Candelore, E. Rands, and R. A. F. Dixon. 1987. Identification of residues required for ligand binding to the β-adrenergic receptor. Proc. Natl Acad. Sci. USA. 84: 4384-4388.
116. Surratt, C. K., P. S. Johnson, A. Moriwaki, B. K. Seidleck, C. J. Blaschak, J. B. Wang, and G. R. Uhl. 1994. Opiate receptor. Charged transmembrane domain amino acids are critical for agonist recognition and intrinsic activity. J. Biol. Chem. 269:20548-20553.
117. Szmuszkovicz, J., and P. F. Von Voightlander. 1982. Benzeneacetamide amines: structurally novel non-μ,-opioids. J. Med. Chem. 25:1125-1126.
118. Takemori, A. E., and P. S. Portoghese. 1985. Affinity labels for opioid receptors. Annu. Rev. Pharmacol. Toxicol. 25:193-223.
119. Thirstrup, K., C. E. Elling, S. A. Hjorth, and T. W. Schwartz. 1996. Construction of a high affinity zinc switch in the κ-opioid receptor. J. Biol. Chem. 271:7875-7878.
120. Unger, V. M., P. A. Hargrave, J. M. Baldwin, and G. F. X. Schertler. 1997. Arrangement of rhodopsin transmembrane α-helices. Nature. 389: 203-206.
121. Unger, V. M., and G. F. X. Schertler. 1995. Low resolution structure of bovine rhodopsin determined by electron cryo-microscopy. Biophys. J. 68:1776-1786.
122. Urbanczyk-Lipkowska, Z., and M. C. Etter. 1987. The crystal structure of a bimorphinan with highly selective kappa opioid receptor antagonist activity. J. Mol. Struct. 159:287-295.
123. 297 of the human δ-opioid receptor in binding of δ-selective ligands. J. Biol. Chem. 271:18789-18796.
124. Varga, E. V., X. Li, D. Stropova, T. Zalewska, R. S. Landsman, R. J. Knapp, V. J. Hruby, W. R. Roeske, and H. I. Yamamura. 1996. The third extracellular loop of the human δ-opioid receptor determines the selectivity of δ-opioid agonists. Mol. Pharmacol. 50:1619-1624.
125. Verlinde, C. L., N. M. Blaton, C. J. De Ranter, and O. M. Peeters. 1984. 5-Ethyl-2′-hydroxy-2-[(1-hydroxycyclopropyl)methyl]-9,9-dimethyl-6,7- benzomorphan hydrochloride (bremazocine). Acta Crystallogr. C. 40:1759-1761.
126. 2A-adrenergicreceptors: identification of amino acids involved in ligand binding and receptor activation by agonists. Mol. Pharmacol. 40:168-179.
127. 2 receptor: identification of amino acid necessary for ligand binding and receptor activation. Mol. Pharmacol. 43:931-940.
128. Wang, J. B., P. S. Johnson, J. M. Wu, W. F. Wang, and G. R. Uhl. 1994. Human κ-opiate receptor second extracellular loop elevates dynorphin's affinity for human μ/κ-chimeras. J. Biol. Chem. 269:25966-25969.
129. Wang, W. W., M. Shahrestanifar, J. Jin, and R. D. Howells. 1995. Studies on the μ and δ opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. Proc. Natl. Acad. Sci. USA. 92:12436-12440.
130. Watson, S., and S. Arkinstall. 1994. The G-Protein Linked Receptor Facts Book. Academic Press, San Diego. 1-294.
131. Wess, J., D. Gdula, and M. R. Brann. 1991. Site-directed mutagenesis of the m3 muscarinic receptor: identification of a series of threonine and tyrosine residues involved in agonist but not antagonist binding. EMBO. J. 10:3729-3734.
132. 5]enkephalin (DPDPE): a molecular mechanics study. J. Computer-Aided Mol. Design. 5:293-302.
133. Wong, S. K.-F., C. Slaughter, A. Ruoho, and E. M. Ross. 1988. The catecholamine binding site of the β-adrenergic receptor is formed by juxtaposed membrane-spanning domains. J. Biol. Chem. 263: 7925-7928.
134. Yu, H., M. Kono, T. D. McKee, and D. D. Oprian. 1995. General method for mapping tertiary contacts between amino acid residues in membrane-embedded proteins. Biochemistry. 34:14963-14969.
135. Xue, J.-C., C. Chen, J. Zhu, S. P. Kunapuli, J. K. de Riel, L. Yu, and L.-Y. Liu-Chen. 1994. Differential binding domains of peptide and non-peptide ligands in the cloned rat κ-opioid receptor. J. Biol. Chem. 269:30195-30199.
136. Xue, J.-C., C. Chen, J. Zhu, S. P. Kunapuli, J. K. de Riel, L. Yu, and L.-Y. Liu-Chen. 1995. The third extracellular loop of the μ-opioid receptor is important for agonist selectivity. J. Biol. Chem. 270:12977-12979.
137. Zaki, P. A., E. J. Bilsky, T. W. Vanderah, J. Lai, C. J. Evans, F. Porreca. 1996. Opioid receptor types and subtypes: the δ-receptor as a model. Annu. Rev. Pharmacol. Toxicol. 36:379-401.
138. Zhou, W., C. Flanagan, J. A. Ballesteros, K. Konvicka, J. S. Davidson, H. Weinstein, R. P. Millar, and S. C. Sealfon. 1994. A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. Mol. Pharmacol. 45:165-170.
139. Zhu, J., J. Yin, P.-Y. Law, P. A. Claude, K. C. Rice, C. J. Evans, C. Chen, L. Yu, and L.-Y. Liu-Chen. 1996a. Irreversible binding of cis-(+)-3-methylfentanyl isothiocyanate to the δ-opioid receptor and determination of its binding domain. J. Biol. Chem. 271:1430-1434.
140. Zhu, J., J.-C. Xue, P.-Y. Law, P. A. Claude, L.-Y. Luo, J. Yin, C. Chen, and L.-Y. Liu-Chen. 1996b. The region in the μ opioid receptor conferring selectivity for sufentanil over the δ receptor is different from over the K receptor. FEBS Lett. 384:198-202.
141. Zhukovsky, E. A., P. R. Robinson, and D. D. Oprian. 1992. Changing the location of the Schiff base counterion in rhodopsin. Biochemistry. 31: 10400-10405.